Lung cancer drug TRX-221 trial halted early – what we know
Disease control
Terminated
This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if TRX-221 was safe and could shrink tumors. The trial was stopped early after enrolling …
Phase: PHASE1, PHASE2 • Sponsor: Therapex Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:49 UTC